Elanco Animal Health Incorporated (ELAN) |
| 23.995 0.305 (1.29%) 05-28 15:17 |
| Open: | 23.8 |
| High: | 24.4 |
| Low: | 23.29 |
| Volume: | 3,792,722 |
| Market Cap: | 11,984(M) |
| PE Ratio: | -47.99 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 30.71 |
| Resistance 1: | 26.29 |
| Pivot price: | 21.89 |
| Support 1: | 22.03 |
| Support 2: | 19.40 |
| 52w High: | 27.72 |
| 52w Low: | 13.09 |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
| EPS | -0.500 |
| Book Value | 13.020 |
| PEG Ratio | 4.04 |
| Gross Profit | 5.386 |
| Profit Margin (%) | -4.95 |
| Operating Margin (%) | 12.33 |
| Return on Assets (ttm) | 1.5 |
| Return on Equity (ttm) | -3.8 |
Wed, 27 May 2026
Elanco (NYSE: ELAN) investors reelect board and ratify 2026 auditor - Stock Titan
Wed, 27 May 2026
ELAN: Innovation and strong execution drive growth, with robust margins and disciplined strategy - TradingView
Tue, 26 May 2026
[Form 4] Elanco Animal Health Inc Insider Trading Activity - Stock Titan
Tue, 26 May 2026
Elanco (NYSE: ELAN) director granted deferred and restricted stock units - Stock Titan
Mon, 25 May 2026
Elanco Animal Health (ELAN) Stock Analysis: Exploring Potential 37% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Mon, 18 May 2026
Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market - PR Newswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |